MedTrace Logo

Tumor Mutational Burden in Lung Cancer Patients

NCT04289259 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2021-06-24

No results posted yet for this study

Summary

Tumor mutational burden (TMB) seems to be is an important marker for immune checkpoint inhibitors efficacy. This study aims to assess the feasibility of the TMB assessment in first-line lung cancer in routine practice both on biopsy and surgical tumor samples. Results will be an element of discussion for the generalization of the TMB implementation in cancer centers.

Conditions

  • Non Small Cell Lung Cancer
  • Non-Small Cell Carcinoma of Lung
  • Non Small Cell Lung Cancer Stage III
  • Non-small Cell Lung Cancer Stage IV

Interventions

OTHER

TMB assessment

Tumor mutational burden could be calculated by cancer gene panel (CGP), whole-exome sequencing (WES), RNA-sequencing (RNA-seq), FoundationOne CDx assay panel (FMI).

Sponsors & Collaborators

Principal Investigators

  • Jacques Cadranel, MD · AP-HP - Hôpital Tenon

  • Benjamin Besse, MD · Gustave Roussy, Cancer Campus, Grand Paris

  • Pierre Laurent-Puig, MD · AP-HP - Hôpital Européen Georges-Pompidou

  • Etienne Rouleau, PharmD, PhD · Gustave Roussy, Cancer Campus, Grand Paris

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-10
Primary Completion
2020-07-06
Completion
2020-07-06

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04289259 on ClinicalTrials.gov